Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
To compare the effect of the rapid-acting insulin analogues (RAIAs) NovoRapid (aspart) and
Prandilin (lispro) on glycemic variations by Continuous glucose monitoring system (CGMS) in
continuous subcutaneous insulin infusion (CSII) with metformin intensive therapy in newly
diagnosed type 2 diabetes mellitus (T2DM).
Phase:
Phase 4
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University